Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

ALS Untangled says MitoQ merits a small pilot trial

Original source

Mito QALSUntangled · 19 July 2015

MitoQ has shown positive preclinical results in two ALS models and appears reasonably safe and inexpensive at 10 mg daily, according to an ALS Untangled review. The review says available anecdotal reports are not enough to determine whether it helps people with ALS.

Why this matters

MitoQ may be worth studying in people with ALS, but these findings do not currently change treatment. A small open-label pilot study with confirmed ALS diagnoses and validated outcomes would be needed to assess its potential benefit.

Limitations and context

This is an independent expert review published by ALS Untangled, not a clinical trial. The evidence described is preclinical and anecdotal; no benefit for people with ALS has been established. The review recommends, rather than reports results from, a pilot study.

Relevant to you?